Development of flexible-heteroarotinoids for kidney cancer

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1227-1238

  Liu, Tongzu ^a,b   Masamha, Chioniso Patience ^a   Chengedza, Shylet ^a   Berlin, K Darrell ^c   Lightfoot, Stan ^a   He, Feng ^a   Benbrook, Doris Mangiaracina ^a,d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c OKLAHOMA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN D1; DRUG METABOLITE; GLUTATHIONE; HETEROAROTINOID SHETA2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; UVOMORULIN;

AMES TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY TUBULE; MORTALITY; MOUSE; NONHUMAN; NUDE MOUSE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CHROMANS; CYCLIN D1; GLUTATHIONE; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICE, NUDE; MUTAGENICITY TESTS; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; RATS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; THIONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66849124550     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1069     Document Type: Article

References (38)

1. Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int 2001;88:818-824 (Pubitemid 33071052)
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611-1623
3. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177-186 (Pubitemid 30205372)
4. Schrader AJ, von Knobloch R, Heidenreich A, Buer J, Hofmann R. Application of retinoids in the treatment of renal cell carcinoma-a futile effort? Anticancer Drugs 2004;15:819-824
5. Benbrook DM, Kamelle SA, Guruswamy SB, et al. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor antagonists. Invest New Drugs 2005;23:417-428 (Pubitemid 41166547)
6. Liu S, Brown CW, Berlin KD, et al. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem 2004;47:999-1007. (Pubitemid 38176803)
7. Liu T-Z, Hannafon B, Gill L, Kelly B, Benbrook DM. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol Cancer Ther 2007;6:1814-1822 (Pubitemid 46954058)
8. Mic FA, Molotkov A, Benbrook DM, Duester G. Retinoid activation of RAR but not RXR is sufficient for mouse embryonic development. Proc Natl Acad Sci U S A 2003;100:7135-7140
9. Le W-D, Berlin KD, Benbrook DM. Modified heteroarotinoids as potential anticancer agents - improved synthesis of 2-nitrotetralin and 2-aminotetralin. J Saudi Chem Soc 2007;11:351-360
10. Guruswamy S, Lightfoot S, Gold M, et al. Effects of retinoids on cancerous phenotype and apoptosis in organotypic culture of ovarian carcinoma. J Nat Cancer Inst 2001;93:516-525 (Pubitemid 32318430)
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitiave PCR and the 2-DDCT method. Methods 2001;25:402-408
12. Liu Z, Zhang Y, Hua YF, Covey JM, Benbrook DM, Chan KK. Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2 using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2008;22:3371-3381
13. HowardEW,CammKD,Wong YC,Wang XH. E-cadherin upregulation as a therapeutic goal in cancer treatment. Mini Rev Med Chem 2008;8:496-518.
14. Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK. Loss of E-cadherin leads to upregulation of NFκB activity in malignant melanoma. Oncogene 2004;23:8509-8519 (Pubitemid 39540801)
15. Scheidereit C. IkB kinase complexes: gateways to NF-kB activation and transcription. Oncogene 2006;25:6685-6705 (Pubitemid 44657846)
16. Le TC, Berlin KD, Benson SD, et al. Heteroarotinoids with anti-cancer activity against ovarian cancer cells. Open Med Chem J 2007;1:11-23.
17. Zani F, Bellotti A, Mazza P. Biological studies on 2,1-benzisothiazole derivatives. II. Evaluation of antimicrobial and genotoxic properties of bz-nitro-, 3-ethylacetate-, 3-amino- and 3-substituted amino 2,1-benzisothiazoles. Farmaco 1994;40:713-719
18. Benbrook DM, Lightfoot S, Ranger-Moore J, et al. Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. Gene Regulation and Systems Biology 2008;2:21-42.
19. Hayakawa M, Miyashita H, Sakamoto I, et al. Evidence that reactive oxygen species do not mediate NF-kB activation. EMBO 2003;22:3356-3366 (Pubitemid 36834865)
20. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-κB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 2005;7:395-403. (Pubitemid 40279807)
21. Chun K-H, Benbrook DM, Berlin KD, Hong WK, Lotan R. Induction of apoptosis in head and neck squamous cell carcinoma (HNSCC) cell lines by heteroarotinoids through a mitochondrial dependent pathway. Cancer Res 2003;63:3826-3832 (Pubitemid 36793073)
22. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007;7:355-359 (Pubitemid 47289259)
23. Jaeschke H, Bajt ML. Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci 2006;89:31-41. (Pubitemid 43013752)
24. Lin Y-D, Chen S, Yue P, et al. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res 2008;68:5335-5344
25. Lin Y, Liu X, Yue P, et al. c-FLIP Down-regulation is an important mechanism underlying Flex-Het-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther 2008;7:3556-3565
26. Boulares AH, Giardina C, Inan MS, Khairallah EA, Cohen SD. Acetaminophen inhibits NF-κB activation by interfering with the oxidant signal in murine Hepa 1-6 cells. Toxicol Sci 2000;55:370-375 (Pubitemid 30353245)
27. Zhang Y, Hua Y, Benbrook DM, Covey JM, Chan KK. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother Pharmacol 2006;58:561-569 (Pubitemid 44167380)
28. Myers T, Chengedza S, Lightfoot S, et al. Flexible Heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs 2008. Published online: 18 September 2008.
29. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19:5785-5799
30. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007;26:711-724 (Pubitemid 46204250)
31. Migita T, Oda Y,Masuda K, et al. Inverse relationship between E-cadherin and p27Kip1 expression in renal cell carcinoma. Int J Oncol 2008;33:41-47
32. Esteban MA, Tran MGB, Harten SK, et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006;66:3567-3575
33. Krishnamachary B, Zagzag D, Nagasawa H, et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 2006;66:2725-2731
34. Tsujimoto Y, Komori K, Tsujimoto M, et al. [Immunohistochemical studies of p53, Ki-67, E-cadherin and β-catenin on renal pelvic and ureteral cancers]. Nippon Hinyokika Gakkai Zasshi 2008;99:1-6.
35. Gervais ML, Henry PC, Saravanan A, et al. Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. Lab Invest 2007;87:1252-1264 (Pubitemid 350126708)
36. Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 2008;25:621-628
37. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. [see comment]. Br J Cancer 2001;84:1424-1431 (Pubitemid 32522115)
38. Brown CW, Liu S, Klucik J, et al. Novel heteroarotinoids as potential antagonists of mycobacterium bovis BCG. J Med Chem 2004;47:1008-1017 (Pubitemid 38176804)